Fierce Pharma3d
Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery deal; Taiho's ADC buyout; WuXi's rosy 2025 outlook
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
Fierce Biotech3d
Eisai's abandoned Enhertu challenger set to live on at BlissBio
BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...
The Pharma Letter4d
Milestone launch for Daiichi Sankyo’s Datroway in Japan
Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the ...
Pharmabiz4d
Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer
Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...
Fierce Pharma5d
AstraZeneca offers early look at Datroway-Tagrisso combo in EGFR lung cancer as phase 3 trial rolls on
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...